Literature DB >> 21328266

Interventions for smokeless tobacco use cessation.

Jon Ebbert1, Victor M Montori, Patricia J Erwin, Lindsay F Stead.   

Abstract

BACKGROUND: Use of smokeless tobacco (ST) can lead to nicotine addiction and long-term use can lead to health problems including periodontal disease, cancer, and cerebrovascular and cardiovascular disease.
OBJECTIVES: To assess the effects of behavioural and pharmacologic interventions for the treatment of ST use. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, Web of Science, PsycINFO, Dissertation Abstracts Online, and Scopus. Date of last search: October 2010. SELECTION CRITERIA: Randomized trials of behavioural or pharmacological interventions to help users of ST to quit with follow up of at least six months. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. We summarised as odds ratios. For subgroups of trials with similar types of intervention and without substantial statistical heterogeneity, we estimated pooled effects using a Mantel-Haenszel fixed-effect method. MAIN
RESULTS: Data from one study suggest that varenicline increases ST abstinence rates (Odds Ratio [OR] 1.6, 95% Confidence Interval (CI) 1.08 to 2.36) among Swedish snus users.Two trials of bupropion SR did not detect a benefit of treatment at six months or longer (OR 0.86, 95% CI 0.47 to 1.57). Nicotine replacement therapy (patch, gum, and lozenge) was not observed to increase tobacco abstinence rates (OR 1.14, 95% CI: 0.91 to 1.42). There was statistical heterogeneity among the 14 trials of behavioural interventions; seven of them reported statistically and clinically significant benefits, four suggested benefit but with wide CIs, whilst two had similar intervention and control quit rates and relatively narrow CIs. Heterogeneity was not explained by the design (individual or cluster randomization), whether participants were selected for interest in quitting, or specific intervention components. Most trials included either telephone counselling, an oral examination and feedback about any ST induced mucosal changes, or both. In a post-hoc subgroup analysis there was some evidence that behavioural interventions which include telephone counselling might increase abstinence rates more than interventions with less contact. In one trial an interactive website increased abstinence more than a static website. AUTHORS'
CONCLUSIONS: Varenicline and behavioural interventions may help ST users to quit. Behavioural interventions incorporating telephone counselling or an oral examination are likely to increase abstinence rates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328266     DOI: 10.1002/14651858.CD004306.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  20 in total

Review 1.  Pharmacological interventions for the treatment of smokeless tobacco use.

Authors:  Jon O Ebbert; Karl Fagerstrom
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.

Authors:  Kunal N Karmali; Donald M Lloyd-Jones; Mark A Berendsen; David C Goff; Darshak M Sanghavi; Nina C Brown; Liliya Korenovska; Mark D Huffman
Journal:  JAMA Cardiol       Date:  2016-06-01       Impact factor: 14.676

3.  Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users.

Authors:  Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder
Journal:  Nicotine Tob Res       Date:  2015-05-14       Impact factor: 4.244

4.  Tobacco Use and Subsequent Cessation Among Hospitalized Patients in Mumbai, India: A Longitudinal Study.

Authors:  Gina R Kruse; Vaibhav Thawal; Himanshu A Gupte; Leni Chaudhuri; Sultan Pradhan; Sydney Howard; Nancy A Rigotti
Journal:  Nicotine Tob Res       Date:  2020-03-16       Impact factor: 4.244

5.  Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study.

Authors:  Michael A Gillies; C A McKenzie; C Whiteley; R J Beale; S M Tibby
Journal:  Intensive Care Med       Date:  2012-05-23       Impact factor: 17.440

Review 6.  Nicotine receptor partial agonists for smoking cessation.

Authors:  Kate Cahill; Nicola Lindson-Hawley; Kyla H Thomas; Thomas R Fanshawe; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

7.  The US SimSmoke tobacco control policy model of smokeless tobacco and cigarette use.

Authors:  David T Levy; Zhe Yuan; Yameng Li
Journal:  BMC Public Health       Date:  2018-06-05       Impact factor: 3.295

8.  The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda; Jordi Ibáñez-Nolla
Journal:  Lung       Date:  2014-05-10       Impact factor: 2.584

9.  Randomized Controlled Trial of the Combined Effects of Web and Quitline Interventions for Smokeless Tobacco Cessation.

Authors:  Brian G Danaher; Herbert H Severson; Shu-Hong Zhu; Judy A Andrews; Sharon E Cummins; Edward Lichtenstein; Gary J Tedeschi; Coleen Hudkins; Chris Widdop; Ryann Crowley; John R Seeley
Journal:  Internet Interv       Date:  2015-05-01

10.  A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users.

Authors:  Jon O Ebbert; Ivana T Croghan; Darrell R Schroeder; Richard D Hurt
Journal:  Nicotine Tob Res       Date:  2013-07-19       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.